"Dicarboxylic Acids" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Acyclic acids that contain two carboxyl groups and have the formula HO2C-R-CO2H, where R may be an aromatic or aliphatic group.
| Descriptor ID |
D003998
|
| MeSH Number(s) |
D02.241.081.337
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Dicarboxylic Acids".
Below are MeSH descriptors whose meaning is more specific than "Dicarboxylic Acids".
This graph shows the total number of publications written about "Dicarboxylic Acids" by people in this website by year, and whether "Dicarboxylic Acids" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2013 | 1 | 1 | 2 |
| 2016 | 2 | 0 | 2 |
| 2018 | 2 | 0 | 2 |
| 2019 | 2 | 3 | 5 |
| 2020 | 2 | 0 | 2 |
| 2021 | 2 | 0 | 2 |
| 2022 | 0 | 3 | 3 |
| 2023 | 1 | 1 | 2 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dicarboxylic Acids" by people in Profiles.
-
Bempedoic Acid Falls in Line. J Am Coll Cardiol. 2024 Jul 09; 84(2):163-164.
-
Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial. JAMA Cardiol. 2024 Mar 01; 9(3):245-253.
-
Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: Pooled analysis of data from four phase 3 clinical trials. Atherosclerosis. 2023 08; 378:117182.
-
The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials. Cardiovasc Drugs Ther. 2024 Dec; 38(6):1415-1420.
-
Factors Associated With Enhanced Low-Density Lipoprotein Cholesterol Lowering With Bempedoic Acid. J Am Heart Assoc. 2022 08 02; 11(15):e024531.
-
Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study). Am J Cardiol. 2022 07 01; 174:1-11.
-
Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. J Clin Lipidol. 2022 May-Jun; 16(3):286-297.
-
Greater than expected reduction in low-density lipoprotein-cholesterol (LDL-C) with bempedoic acid in a patient with heterozygous familial hypercholesterolemia (HeFH). J Clin Lipidol. 2021 Sep-Oct; 15(5):649-652.
-
Role of Bempedoic Acid in Clinical Practice. Cardiovasc Drugs Ther. 2021 08; 35(4):853-864.
-
Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials. J Clin Lipidol. 2020 Sep - Oct; 14(5):649-659.e6.